D-gluconate drives Salmonella growth during acute and chronic infection

This study identifies D-gluconate, a host-generated sugar acid that accumulates during gut inflammation, as the primary carbon source fueling *Salmonella* expansion and persistence in both acute and chronic intestinal infections.

The Gist

Imagine your gut as a bustling, crowded city. Usually, the "good guys" (your healthy gut bacteria) live there peacefully, guarding the gates and making sure no invaders can get in. They do this by eating all the available food, leaving nothing for the bad guys.

But sometimes, the city gets into a fight. When you get an infection or take antibiotics, the city's defenses go into overdrive. The immune system sends out "firefighters" (immune cells) that release powerful chemicals to fight the infection.

Here is the twist: These firefighters accidentally create a new, super-delicious buffet for the bad guys.

The Story of the "Sugar Acid" Buffet

This paper tells the story of Salmonella, a nasty bacteria that causes food poisoning. Scientists wanted to know: How does Salmonella survive and grow so fast when the gut is inflamed?

They discovered that when the gut is under attack, the body's immune system accidentally turns simple sugars (like glucose) into something called sugar acids. Think of it like this:

• Normal Sugar (Glucose): A plain, simple cookie.
• Sugar Acid (Gluconate): A fancy, oxidized cookie that the immune system made by accident while trying to fight the fire.

The Main Character: D-Gluconate

The researchers found that among all these accidental "fancy cookies," one specific type called D-gluconate is the absolute favorite of Salmonella.

• The Analogy: Imagine the gut is a restaurant. Usually, the healthy bacteria eat all the plain cookies. But when the immune system starts fighting, it starts baking a special batch of "D-gluconate cookies" that only Salmonella knows how to eat.
• The Result: Salmonella rushes to this new buffet. Because the healthy bacteria don't know how to eat these specific cookies, Salmonella gets a free pass to eat, grow, and multiply without competition.

The "Glucose" vs. "Galactose" Rivalry

The scientists tested two types of sugar acids:

1. From Glucose (The Main Sugar): These turned into D-gluconate, which Salmonella loved. It was like finding a golden ticket.
2. From Galactose (A Minor Sugar): These turned into different sugar acids that Salmonella couldn't really use. It was like finding a menu written in a language they didn't speak.

The Takeaway: The "Glucose" path is the winner. Salmonella uses D-gluconate as its main fuel source to take over the gut during an infection.

Why This Matters for Long-Term Sickness

The study also looked at what happens in long-term infections (like in people with chronic gut diseases such as Crohn's or Ulcerative Colitis).

• Short-term: Salmonella uses D-gluconate to get a head start.
• Long-term: If the inflammation keeps going, the supply of these "fancy cookies" keeps coming. Salmonella becomes dependent on them. If you stop them from eating D-gluconate, they get weak and can't survive as well in the inflamed gut.

Interestingly, the study found that the genes needed to eat these sugar acids are common in E. coli bacteria found in both healthy people and people with gut diseases. This suggests that these bacteria are like "opportunists." They are always carrying the tools to eat this special food, waiting for the moment the gut gets inflamed so they can feast.

The Big Picture

Think of the inflamed gut as a construction site.

• The Firefighters (Immune System): They are trying to fix the problem but are creating a pile of debris (sugar acids) that the bad guys (Salmonella) can use to build a fortress.
• The Solution: If we can figure out how to stop the gut from making these specific "fancy cookies" (D-gluconate), or if we can teach the good bacteria how to eat them, we might be able to starve the bad bacteria and stop the infection without using heavy antibiotics.

In simple terms: When your gut gets angry and inflamed, it accidentally cooks up a special meal that only the bad bacteria can eat. This paper found that the most important ingredient in that meal is D-gluconate, and stopping Salmonella from eating it could be a new way to cure gut infections.

Technical Summary

1. Problem Statement

• Context: Salmonella enterica serovar Typhimurium (S. Typhimurium) overcomes gut colonization resistance by exploiting nutrient niches created during inflammation. While monosaccharides (e.g., glucose, fructose) are known drivers of colonization, the role of their oxidized derivatives—sugar acids (aldonic, uronic, and aldaric acids)—remains understudied.
• Knowledge Gap: Sugar acids are generated in the gut lumen via host-driven oxidative processes (specifically by reactive nitrogen species, RNS, from inducible nitric oxide synthase, iNOS) rather than dietary intake. It is unclear which specific sugar acids (derived from D-glucose vs. D-galactose) constitute the primary metabolic niche for Salmonella during acute and chronic infection, and how this varies between bacterial strains.
• Hypothesis: The study posits that specific sugar acids, particularly those derived from the abundant dietary monosaccharide D-glucose, serve as critical, inflammation-dependent carbon sources that fuel Enterobacteriaceae expansion in the inflamed gut.

2. Methodology

The researchers employed a multi-faceted approach combining in vivo mouse models, in vitro metabolic assays, and bioinformatic analysis:

• Mouse Infection Models:
  • Acute Model: Streptomycin-pretreated C57BL/6J mice (susceptible to systemic infection) to model acute inflammation and RNS production.
  • Chronic Model: Streptomycin-pretreated 129S6/SvEvTac mice (resistant to systemic spread due to functional Nramp1) to study long-term persistence (up to 9 days).
  • LPS Model: Mice injected with Lipopolysaccharide (LPS) to induce ROS-mediated inflammation without the high RNS levels of the streptomycin model.
• Ecological Invasion Assays: A novel competitive strategy where a mutant strain (defective in sugar acid utilization) is introduced in vast excess (99.9%), while the Wild Type (WT) is a minority (0.1%). This tests if the WT can exploit the "niche" left vacant by the mutant to expand to comparable levels, avoiding pleiotropic fitness defects often seen in standard 1:1 competitions.
• Genetic Engineering: Construction of single and multimutants in S. Typhimurium SL1344 targeting key enzymes in sugar acid catabolism:
  • D-Glucose derivatives: ΔidnK/ΔgntK (D-gluconate), ΔuxuB (D-glucuronate), ΔgudD (D-glucarate).
  • D-Galactose derivatives: ΔdgoK (D-galactonate), ΔuxaB (D-galacturonate), ΔgarD (D-galactarate).
  • Multimutants: Δ4 D-glc (lacking all D-glucose sugar acid pathways) and Δ3 D-gal (lacking all D-galactose pathways).
• Metabolomics: LC-MS quantification of monosaccharides and sugar acids in cecal contents from SPF, streptomycin-treated, and LPS-treated mice.
• In Vitro Growth: Growth curves in minimal media with sugar acids as sole carbon sources to assess metabolic potential.
• Bioinformatics: Analysis of metagenomic datasets from IBD patients and healthy controls to determine the prevalence of sugar acid utilization pathways in Escherichia coli.

3. Key Contributions

• Identification of D-Gluconate as the Dominant Niche: The study definitively identifies D-gluconate (an aldonic acid) as the most critical sugar acid driving S. Typhimurium expansion, surpassing more highly oxidized forms like D-glucuronate and D-glucarate.
• Strain-Specific Metabolic Preferences: The research highlights that sugar acid utilization is strain-dependent. While S. Typhimurium ATCC14028s relies heavily on D-galactarate, the SL1344 strain (used here) is driven almost exclusively by D-glucose derivatives.
• Mechanism of Formation: The study confirms that sugar acid accumulation is driven by iNOS-derived RNS (specifically in the streptomycin model) rather than ROS alone (LPS model), explaining why D-gluconate levels are high in the streptomycin model but low in the LPS model.
• Pathobiont Relevance: Demonstrates that the genetic capacity to utilize sugar acids is conserved in E. coli regardless of IBD status, suggesting these pathways are pre-adapted for expansion during inflammation.

4. Key Results

• Ecological Invasion: In streptomycin-pretreated mice, the WT S. Typhimurium successfully expanded to match the density of ΔidnK ΔgntK (D-gluconate deficient) mutants, confirming D-gluconate is a major exploitable niche. In contrast, WT failed to expand significantly when competing against mutants lacking D-galactose sugar acid pathways.
• Metabolic Hierarchy: Among D-glucose derivatives, D-gluconate (C1 oxidation) supported the highest expansion, followed by D-glucuronate (C6 oxidation) and D-glucarate (C1+C6 oxidation). D-galactose derivatives (D-galactonate, D-galacturonate, D-galactarate) provided negligible support for SL1344 expansion.
• Long-Term Infection: In the 129S6/SvEvTac chronic infection model, the Δ4 D-glc mutant showed a severe fitness defect (up to 1,000-fold reduction) compared to WT in the gut lumen over 9 days, whereas the defect was minimal in systemic organs (spleen/liver). This indicates sugar acids are crucial for luminal persistence during chronic inflammation.
• Metabolite Quantification: LC-MS revealed that D-gluconate accumulated to millimolar concentrations in the cecum of streptomycin-treated mice, often exceeding the concentration of free D-glucose. This accumulation was absent in LPS-treated mice, correlating with the lack of fitness defects in the LPS model.
• In Vitro Growth: S. Typhimurium grew robustly on D-gluconate, D-glucuronate, and D-glucarate as sole carbon sources. D-galactose-derived acids failed to support growth (except D-galactarate for ATCC14028s in previous studies), confirming the in vivo findings are due to metabolic capability and substrate availability.
• Genomic Prevalence: Bioinformatic analysis showed that sugar acid utilization genes are equally prevalent in E. coli from IBD and non-IBD patients, supporting the "pathobiont" hypothesis where inflammation selects for pre-existing metabolic traits.

5. Significance

• Mechanistic Insight: The paper elucidates a specific mechanism by which host inflammation (via iNOS/RNS) creates a unique nutrient landscape (sugar acids) that pathogens like Salmonella exploit to outcompete the microbiota.
• Therapeutic Implications: Identifying D-gluconate as a key fuel source suggests that targeting its production (e.g., inhibiting iNOS) or blocking its uptake/metabolism could be a novel anti-infective strategy to prevent Salmonella and other Enterobacteriaceae expansion in inflammatory bowel disease (IBD).
• Ecological Understanding: It refines the understanding of gut colonization resistance, showing that the "niche" is not just about the absence of competitors but the active generation of specific, inflammation-linked metabolites that favor pathogen growth.
• Strain Variability: The findings caution against generalizing metabolic phenotypes across different Salmonella strains, emphasizing the need for strain-specific analysis in infection models.

In summary, this study establishes D-gluconate as a principal, inflammation-dependent nutrient source that drives the expansion of S. Typhimurium and potentially other Enterobacteriaceae in the inflamed gut, offering a new target for therapeutic intervention in infectious and chronic inflammatory diseases.